New 'Living Drug' trial targets Tough-to-Treat cancers
Disease control
Recruiting now
This is a first-in-human study to test the safety and early effectiveness of a new cell therapy called CLDN6 CAR-T, given with or without an RNA vaccine, for patients with advanced solid tumors that have come back or stopped responding to other treatments. The trial will enroll a…
Phase: PHASE1 • Sponsor: BioNTech Cell & Gene Therapies GmbH • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC